Literature DB >> 3926648

Activation of neonatal and adult human macrophages by alpha, beta, and gamma interferons.

C B Wilson, J Westall.   

Abstract

Increasing evidence suggests that gamma interferon (IFN-gamma) is the major or sole factor in human lymphokines which activates blood monocyte-derived macrophages (M phi) to inhibit or kill Toxoplasma gondii and certain other intracellular pathogens. In the current studies, we found that IFN-gamma effectively activated tissue M phi from adults (peritoneal M phi) and from newborns (placental M phi) as well as blood-derived M phi from adults and from newborns to kill or to inhibit the replication of T. gondii. Results with purified and recombinant IFN-gamma and with adult and newborn M phi were similar. IFN-gamma-treated M phi were equally or more active against T. gondii than were freshly isolated monocytes and M phi. Recombinant IFN-alpha A and IFN-beta were less effective than IFN-gamma. IFN-gamma also inhibited survival and replication of T. gondii in WISH cells more effectively than did IFN-alpha and IFN-beta. These findings are consistent with an important role for IFN-gamma in the control of Toxoplasma infection and indicate that the anti-Toxoplasma activity of resting and IFN-gamma-activated adult and neonatal M phi is similar. The increased susceptibility of neonates to T. gondii is not due to a defect in M phi effector function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926648      PMCID: PMC262022          DOI: 10.1128/iai.49.2.351-356.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  SIMPLIFIED MYELOPEROXIDASE STAIN USING BENZIDINE DIHYDROCHLORIDE.

Authors:  L S KAPLOW
Journal:  Blood       Date:  1965-08       Impact factor: 22.113

2.  Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii).

Authors:  J S Remington; T C Merigan
Journal:  Science       Date:  1968-08-23       Impact factor: 47.728

3.  The ontogeny of interferon production by human leukocytes.

Authors:  C G Ray
Journal:  J Pediatr       Date:  1970-01       Impact factor: 4.406

4.  Defective IFN-gamma production in the human neonate. I. Dysregulation rather than intrinsic abnormality.

Authors:  N Wakasugi; J L Virelizier
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

5.  Inhibition of growth of Toxoplasma gondii in cultured fibroblasts by human recombinant gamma interferon.

Authors:  E R Pfefferkorn; P M Guyre
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

6.  Natural human interferon-gamma. Complete amino acid sequence and determination of sites of glycosylation.

Authors:  E Rinderknecht; B H O'Connor; H Rodriguez
Journal:  J Biol Chem       Date:  1984-06-10       Impact factor: 5.157

7.  Cellular defenses against Toxoplasma gondii in newborns.

Authors:  C B Wilson; J E Haas
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

8.  Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon.

Authors:  R D Schreiber; J L Pace; S W Russell; A Altman; D H Katz
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

9.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

10.  Activation of human macrophages. Comparison of other cytokines with interferon-gamma.

Authors:  C F Nathan; T J Prendergast; M E Wiebe; E R Stanley; E Platzer; H G Remold; K Welte; B Y Rubin; H W Murray
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  18 in total

1.  Differential infectivity and division of Toxoplasma gondii in human peripheral blood leukocytes.

Authors:  J Y Channon; R M Seguin; L H Kasper
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

2.  Cytokine receptor signalling in neonatal macrophages: defective STAT-1 phosphorylation in response to stimulation with IFN-gamma.

Authors:  L Maródi; K Goda; A Palicz; G Szabó
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

3.  Dendritic cells as effector cells: gamma interferon activation of murine dendritic cells triggers oxygen-dependent inhibition of Toxoplasma gondii replication.

Authors:  F Aline; D Bout; I Dimier-Poisson
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

4.  Presence of gamma interferon in human acute and congenital toxoplasmosis.

Authors:  J Raymond; M H Poissonnier; P H Thulliez; F Forestier; F Daffos; P Lebon
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 5.  The role of mediators in the response to thermal injury.

Authors:  Y K Youn; C LaLonde; R Demling
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

6.  Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells.

Authors:  C N Nagineni; K Pardhasaradhi; M C Martins; B Detrick; J J Hooks
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  Decreased production of interferon-gamma by human neonatal cells. Intrinsic and regulatory deficiencies.

Authors:  C B Wilson; J Westall; L Johnston; D B Lewis; S K Dower; A R Alpert
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

8.  Mechanisms of killing of Toxoplasma gondii by rat peritoneal macrophages.

Authors:  R E McCabe; J S Remington
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

9.  The phenotype of human placental macrophages and its variation with gestational age.

Authors:  J Goldstein; M Braverman; C Salafia; P Buckley
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

Review 10.  Fc gamma receptors in cancer and infectious disease.

Authors:  M W Fanger; D V Erbe
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.